405TiP - A phase II study of albumin-bound paclitaxel combined with epirubicin and cyclophosphamide as neo-adjuvant therapy in breast cancer women

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Locally Advanced
Presenter Jin Zhang
Authors J. Zhang, S. Zhang, L. Liu, B.X. Zhang
  • The Third Surgical Department Of Breast Cancer, Tianjin Cancer Hospital, 300060 - Tianjin/CN

Abstract

Purpose

To observe whether the efficacy and safety of Albumin-Bound Paclitaxel has advantage over Cremophor-Formulated Paclitaxel as neo-adjuvant therapy in breast cancer

Patients and methods

Twenty-six breast cancer patients were enrolled into Albumin-Bound Paclitaxel group. Albumin-Bound Paclitaxel 260mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide 500mg/m2 was administrated as neo-adjuvant therapy. Twenty-six patients who were treated with Cremophor-Formulated Paclitaxel 175mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide 500mg/m2 as the control group. The objective observation include the pathologic complete response rates, clinical response rates, safety and toxicity. The PI3K, pAKT, mTOR, BAD protein were examined before and after chemotherapy in two groups.

Results

34.6% patients (9/26) in Albumin-Bound Paclitaxel group achieved a clinical complete response, this rate was 11.5% higher than control group which rate was 23.1%(6/26). 15.4% patients (4/26) in Albumin-Bound Paclitaxel group achieved a pathologic complete response, this rate was 11.6% higher than control group which rate was 3.8%(1/26). None patients (0/26) in Albumin-Bound Paclitaxel group occurs neutropenia but 15.4% patients (4/26) in control group occurs neutropenia during chemotherapy. All patients have normal left ventricular ejection fraction range (LVEF > 50%) before and after therapy. The positive rate of PI3K, mTOR, pAKT expression decreased 45.6%,42.5%,41.1% respectively in Albumin-Bound Paclitaxel group after chemotherapy and the control group decreased 13.2%,14.1%,10.1%. The positive rate of BAD expression increased 21.6% in Albumin-Bound Paclitaxel group after chemotherapy and the control group only increased 6.2%.

Conclusion

Albumin-Bound Paclitaxel has advantage in clinical response rate over Cremophor-Formulated Paclitaxel in breast cancer. Albumin-Bound Paclitaxel has no more additional adverse events than Cremophor-Formulated Paclitaxel. Albumin-Bound Paclitaxel has lower incidence of neutropenia than Cremophor-Formulated Paclitaxel. Albumin-Bound Paclitaxel decrease the expression of PI3K, pAKT, mTOR protein and increase the expression of BAD protein more significantly than Cremophor-Formulated Paclitaxel after chemotherapy

Disclosure

All authors have declared no conflicts of interest.